Plain-English translation of NCT06591338 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
After a minor stroke, your doctor may prescribe blood-thinning medications to prevent another stroke from happening. This trial compares two medications—ticagrelor and —to see which one, when combined with aspirin, is most effective and safest. You would take whichever medication you're randomly assigned to for 90 days while researchers track your recovery.
Doctors are not yet sure which blood-thinning medication works best for people recovering from minor strokes caused by large vessel blockages. This study aims to answer that question so future patients can receive the most effective treatment.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either ticagrelor or along with aspirin for 90 days. During that time, you will have clinic visits and brain imaging scans (CT or MRI) to monitor your recovery and check for any side effects. You'll also have blood tests and heart monitoring as needed, with follow-up assessments at one week, seven days, and three months to measure how well the medication is working.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Egypt
Phase
Large-scale testing
Sponsor
Kafrelsheikh University
Enrollment target
~900 participants
Started
September 2024
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
mohamed G. Zeinhom, MD
neurology department kafr el-sheikh university
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.